TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04785261
Drug: Methylhydroxypropylcellulose
Normalized name: hydroxypropylcellulose
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 drips each time, every 4 hours, for 12 weeks.
Study: NCT04785261
Drug: Carbomer
Normalized name: carbomer
DrugBank: Carbomer (DB15649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drip each time, at bedtime, for 12 weeks.
Study: NCT04521647
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use
Study: NCT06190249
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV.
Study: NCT06190249
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV.
Study: NCT06190249
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV.
Study: NCT05364073
Drug: Furmonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib tablet
Study: NCT05459974
Drug: Colchicine 0.6 mg
Normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.6 mg once daily for 30 days after the atrial fibrillation ablation
Study: NCT04662255
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04662255
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral
Study: NCT04662255
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT04662255
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral
Study: NCT06263517
Drug: Clodronate
Normalized name: Clodronate
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Arm 1, patients will be treated with intra articular clodronate 2 mg/2 ml from Baseline to Week 3
Study: NCT06263517
Drug: Clodronate
Normalized name: Clodronate
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Arm 2, patients will be treated with intra articular clodronate 5 mg/2 ml from Baseline to Week 3
Study: NCT06263517
Drug: Clodronate
Normalized name: Clodronate
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Arm 3, patients will be treated with intra articular clodronate 10 mg/2 ml from Baseline to Week 3
Study: NCT04984759
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).
Study: NCT04984759
Drug: Tafenoquine
Normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.
Study: NCT05351788
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
Study: NCT05998317
Drug: At-night Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
Study: NCT05998317
Drug: At-induction Dexamethasone
Normalized name: dexamethasone Injection
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
Study: NCT05351788
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
Study: NCT06144723
Drug: HS-20105
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously every 21 days.
Study: NCT04340258
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks. The drug will be infused through a peripheral line or an indwelling catheter. The first dose will be given 2 weeks prior to surgery. Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months. Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
Study: NCT05213585
Drug: Ivermectin cream
Normalized name: Ivermectin Cream
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application of ivermectin cream to eyelashes of treatment eye.
Study: NCT05401214
Drug: Niraparib plus Abiraterone Acetate (Nira/AA) combination
Normalized name: abiraterone acetate / niraparib Pill
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nira 100 milligrams (mg)/AA 500 mg combination will be administered orally as immediate-release film coated tablets.
Study: NCT05401214
Drug: Prednisone/Prednisolone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone/Prednisolone 10 mg will be administered orally.
Study: NCT05765084
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab (1200 mg) will be administered on day 0 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Atezolizumab should be administered before chemotherapy administration as an IV infusion over 60 (±15) minutes. If the first infusion is tolerated, all subsequent infusions may bedelivered over 30 (±10) minutes. Additional atezolizumab treatment (1680 mg) after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week) as an IV infusion over 30-60 minutes.
Study: NCT05765084
Drug: Platinum/pemetrexed based chemotherapy
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: On the first day of each cycle (day 0), pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes, followed by cisplatin 75 mg/m2 as IV over approximately 2 hours. The actual doses of the drugs to be administered to patients will be determined by calculating the patient's body surface area at the beginning of each cycle. For ease of dose administration, the protocol allows ± 5% variance in the calculated total dose per infusion. If deemed necessary, the treating physician can decide to replace cisplatin by carboplatin. In that case, carboplatin will be delivered to an area under the concentration-time curve (AUC) of 5 as an IV infusion over 1 hour.
Study: NCT04884282
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. Nivolumab is produced from cell culture using a CHO cell line.
Study: NCT04884282
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel is a cytotoxic microtubule inhibiting antineoplastic agent in the taxane class. Docetaxel monotherapy is indicated for locally advanced or metastatic NSCLC after failure of prior platinum- based chemotherapy.
Study: NCT05670457
Drug: Diosmin
Normalized name: Diosmin
DrugBank: Diosmin (DB08995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diosmin 500 mg twice daily
Study: NCT06114537
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The used intervention in this study is acetazolamide, which belongs to a class of drugs known as carbonic anhydrase inhibitors and has been used with other medications to treat high ocular pressure due to certain types of glaucoma~Patients in the treatment group will receive 250 milligrams of oral acetazolamide twice daily for 16 weeks.~Patients randomized to the treatment group will switch to 125 milligrams of oral acetazolamide twice daily for another four weeks when the central foveal thickness (CFT) on OCT is reduced by ≥25% at the evaluation visit at 16 weeks after the baseline visit. These patients will continue with this dose till the end of the study when the CFT on OCT is stable or further reduced. If the CFT on OCT has increased, they switch back to 250 milligrams of oral acetazolamide twice daily for another 12 weeks.
Study: NCT05344209
Drug: Sagramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
Study: NCT05455359
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prucalopride 0.04 mg/kg/day
Study: NCT05455359
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine 0.4 mg/kg/day
Study: NCT05102123
Drug: Cytisine
Normalized name: Cytisine
DrugBank: Cytisine (DB09028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation
Study: NCT04893759
Drug: Pelcitoclax
Normalized name: Pelcitoclax
DrugBank: Pelcitoclax (DB16285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle
Study: NCT06404736
Drug: Bispecific antibody (bsAb) targeting PD-1 and CLTA-4
Normalized name: Anti-pd-1/tim-3 bispecific antibody ro7121661
DrugBank: Lomvastomig (DB19060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
Study: NCT06404736
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin is a chemotherapy medication belonging to the platinum-based class of drugs, commonly used in the treatment of various cancers, including ovarian cancer, lung cancer, and bladder cancer. It functions by forming DNA adducts, disrupting DNA replication and transcription processes in cancer cells, ultimately leading to cell death. Despite its efficacy, carboplatin can cause side effects such as nausea, vomiting, and bone marrow suppression.
Study: NCT04970602
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
Study: NCT05059145
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal cream 1%
Study: NCT05059145
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg oral capsule
Study: NCT06278727
Drug: angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Guideline-directed Medical Therapy (GDMT) includes those 4 drugs, and only taking at least 3 drugs could be recognized as GDMT.
Study: NCT04910711
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir-based antiretroviral therapy
Study: NCT04910711
Drug: Levonorgestrel implant
Normalized name: levonorgestrel IMPLANT KIT
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women initiating the levonorgestrel implant
Study: NCT04910711
Drug: Depo medroxyprogesterone acetate injection
Normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women initiating the depo medroxyprogesterone acetate injection
Study: NCT04990037
Drug: CAN04
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05280509
Drug: TL-895
Normalized name: TL-895
DrugBank: TL-895 (DB16471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
Study: NCT05280509
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
Study: NCT04932083
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added.
Study: NCT04932083
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added.
Study: NCT04932083
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added.
Study: NCT06721819
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three doses of IV acetaminophen (as following ERAS protocol) at 1000mg per dose within 48 hours post operatively.
Study: NCT05010499
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: femoral nerve block receives 20 ml of levobupivacaine 0.25%
Study: NCT05010499
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fascia iliaca block receives 40 ml of levobupivacaine 0.25%
Study: NCT05095077
Drug: Tadalafil 40 MG
Normalized name: tadalafil 40 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose on study day 1/2
Study: NCT04870905
Drug: Tis-U-Sol
Normalized name: Tis-U-Sol
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tislelizumab 200mg will be given every 3 weeks for 12 cycles
Study: NCT04113226
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.
Study: NCT04113226
Drug: Lenalidomide 20 MG
Normalized name: lenalidomide 20 MG
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with Rituximab plus Lenalidomide. Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression
Study: NCT04800263
Drug: SHR-1905
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1905 will be injected subcutaneously
Study: NCT04999800
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer
Study: NCT04999800
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor
Study: NCT05390515
Drug: Tildrakizumab Prefilled Syringe
Normalized name: tildrakizumab Prefilled Syringe
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IL-23 inhibitor
Study: NCT04788953
Drug: Solriamfetol Oral Tablet
Normalized name: solriamfetol Oral Tablet
DrugBank: Solriamfetol (DB14754)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The administered drug is SUNOSI (solriamfetol) tablets for oral use. Initial U.S. Approval: 2019
Study: NCT05063162
Drug: Rozanolixizumab
Normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive pre-specified doses of rozanolixizumab.
Study: NCT06260059
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient will be given 10 mg of Empagliflozin if randomized to the drug arm or will receive placebo drug for 1 year
Study: NCT00027209
Drug: prempro
Normalized name: Prempro
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05501340
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks
Study: NCT05501340
Drug: Molgramostim
Normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200ug qd subcutaneous injection for 7 days
Study: NCT06266091
Drug: M701
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intra-peritoneal infusion of M701 combined with system therapy
Study: NCT06266091
Drug: paracentesis
Normalized name: Lidocaine Hydrochloride 1% Injection Kit [PARACENTESIS TRAY]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paracentesis combined with system therapy
Study: NCT04707196
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT04707196
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intramuscularly
Study: NCT04062708
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Preoperative Treatment:~* Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~* Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles.
Study: NCT06383702
Drug: pregabalin sustained-release tablets
Normalized name: pregabalin Extended Release Oral Tablet
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will take pregabalin sustained-release tablets for the duration of 14 weeks. The dosage will include 165 mg daily (for the titration and the withdraw period) and 330 mg daily for the fixed-dose period.
Study: NCT06445075
Drug: Apitegromab
Normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.
Study: NCT06445075
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide will be administered every week by subcutaneous injection.
Study: NCT06445075
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide will be administered every week by subcutaneous injection.
Study: NCT05633407
Drug: Efgartigimod
Normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Efgartigimod IV 10 mg/kg infusion qw for 24 weeks. Participants will be randomized to receive efgartigimod IV 10 mg/kg or matching placebo in a 2:1 ratio, respectively
Study: NCT05012371
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO